Table 3.
Antimicrobial regimens prescribed
| Dosing Regimens Utilized | Success (n = 100) | Failure (n = 100) | Total (n = 200) | Appropriately dosed* |
|---|---|---|---|---|
| Monotherapy Regimens | ||||
| Amoxicillin-clavulanate 875 mg twice daily | 4 | 1 | 5 | X |
| Cefuroxime 500 mg three times daily | 0 | 1 | 1 | X |
| Cephalexin 500 mg twice daily | 5 | 8 | 13 | |
| Cephalexin 1000 mg twice daily | 2 | 2 | 4 | |
| Cephalexin 500 mg three times daily | 7 | 6 | 13 | |
| Cephalexin 1000 mg three times daily | 0 | 3 | 3 | X |
| Cephalexin 500 mg four times daily | 18 | 9 | 27 | X |
| Clindamycin 300 mg twice daily | 0 | 2 | 2 | |
| Clindamycin 150 mg three times daily | 0 | 1 | 1 | |
| Clindamycin 300 mg three times daily | 1 | 4 | 5 | |
| Clindamycin 300 mg four times daily | 1 | 3 | 4 | X |
| Clindamycin 450 mg three times daily | 3 | 4 | 7 | X |
| Doxycycline 100 mg twice daily | 28 | 20 | 47 | X |
| SMX/TMP 1 DS tablet twice daily | 18 | 17 | 36 | |
| SMX/TMP 2 DS tablets twice daily | 3 | 5 | 8 | X |
| Dual Therapy Regimens | ||||
| Amoxicillin-clavulanate 875 mg twice daily & doxycycline 100 mg twice daily | 0 | 1 | 1 | X |
| Amoxicillin-clavulanate 875 mg twice daily & SMX/TMP 1 DS tablet twice daily | 0 | 1 | 1 | |
| Cephalexin 500 mg twice daily & doxycycline 100 mg twice daily | 0 | 1 | 1 | |
| Cephalexin 500 mg four times daily & doxycycline 100 mg twice daily | 2 | 0 | 2 | X |
| Cephalexin 1000 mg two times daily & doxycycline 100 mg twice daily | 0 | 1 | 1 | |
| Cephalexin 500 mg twice daily & SMX/TMP 1 DS tablet twice daily | 0 | 1 | 1 | |
| Cephalexin 1000 mg twice daily & SMX/TMP 1 DS tablet twice daily | 0 | 3 | 3 | |
| Cephalexin 500 mg three times daily & SMX/TMP 1 DS tablet twice daily | 1 | 1 | 2 | |
| Cephalexin 500 mg four times daily & SMX/TMP 1 DS tablet twice daily | 5 | 4 | 9 | |
| Cephalexin 1000 mg four times daily & SMX/TMP 1 DS tablet twice daily | 0 | 1 | 1 | |
| Doxycycline 100 mg twice daily & SMX/TMP 1 DS tablet twice daily | 2 | 0 | 2 | |
*
Appropriately dosed defined as meeting minimum dosing recommendation in Table 1.